Aerie CEO Vince Anido leaves

  • Push-out Score determined
  • After around eight years in the position
  • Praise for Anido
  • Benjamin McGraw taking over temporarily
  • Search for a successor
  • Anido kept it short and said 36 words

(exechange) — Durham, North Carolina, September 21, 2021 — Vince Anido, chief executive of Aerie, leaves. As announced by Aerie Pharmaceuticals Inc. in a news release and in a regulatory filing published on Tuesday, September 21, 2021, Vicente (Vince) Anido has left his post as chief executive officer at the ophthalmic pharmaceutical company, after around eight years in the role, effective September 17, 2021.

Aerie will undertake a search for a successor.

Vince Anido’s duties as CEO will be taken over temporarily by Benjamin F. McGraw, most recently Lead Independent Director at Aerie Pharmaceuticals Inc., as Interim Executive Chairman.

No reason given

In the announcement, Aerie did not explicitly explain the reason for the move.

Precise information regarding Vince Anido’s future plans was not immediately available.

“No longer serves”

Aerie said: “[E]ffective September 17, 2021, Vicente Anido, PhD. no longer serves as the Company’s Chairman and Chief Executive Officer or as a director of the Company.”

Share price decline since September 2018

The announcement follows a decline in Aerie Pharmaceuticals Inc.’s share price of 81% since September 2018.

In the position of CEO since 2013

Vince Anido became CEO of the Company in 2013.

Vicente Anido, Jr., Ph.D. has served as the Company’s Chief Executive Officer since July 2013 and as Chairman of the Company’s Board since April 2013.

Anido is the former President, Chief Executive Officer and Director of ISTA Pharmaceuticals, Inc., which was acquired by Bausch + Lomb, Inc. in 2012.

Prior to joining ISTA Pharmaceuticals, Anido served as General Partner of Windamere Venture Partners from 2000 to 2001.

From 1996 to 1999, Anido served as President and Chief Executive Officer of CombiChem, Inc., a drug discovery company.

From 1993 to 1996, Anido served as President of the Americas Region of Allergan, Inc., where he was responsible for Allergan’s commercial operations for North and South America.

Prior to joining Allergan, Anido spent 17 years at Marion Laboratories and Marion Merrell Dow, Inc., including as Vice President, Business Management of Marion’s U.S. Prescription Products Division.

Anido previously served as a member of the board of directors of QLT Inc. from 2012 to 2013, Depomed, Inc. from February 2013 to May 2016 and Nicox S.A. from June 2013 to June 2014.

In addition, from 2002 to 2008, Anido served as a member of the board of directors of Apria Healthcare, Inc.

Anido holds a B.S. and a M.S. from West Virginia University and a Ph.D. from the University of Missouri, Kansas City.

Push-out Score determined

The Push-out Score™ determined by exechange gauges the pressure surrounding Vince Anido’s move on a scale of 0 to 10.

exechange reached out to Aerie and offered the company the opportunity to comment on the score.

Read the full story in the exechange report 39.2021 ($).